» Articles » PMID: 35967567

Management of Neuropathic Bladder Secondary to Spina Bifida: Twenty Years' Experience with a Conservative Approach

Overview
Journal Front Pediatr
Specialty Pediatrics
Date 2022 Aug 15
PMID 35967567
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Although different management strategies and protocols are available in the literature, reliance on expert opinion remains fundamental. A conservative approach can be utilized, but patients must be closely monitored throughout the management process. The objective of this study was to review the management and outcomes of neuropathic bladder in spina bifida by appraising long-term bladder and renal function in patients treated at a medical center utilizing a conservative management style.

Methods: This is a single-center retrospective review of urology care for all spina bifida patients 5-19 years of age with a neuropathic bladder who attended follow-ups between April 2000 and April 2020. Only patients with more than 5 years of follow-up were included. Renal functions, continence and results of invasive video urodynamics (IUD) and any surgical interventions were recorded.

Results: Seventy-one patients (mean age = 10.5 years) were identified after exclusions. Bladder compliance between first and last IUDs increased significantly ( = 0.0056). Anticholinergic treatment was started at the first outpatient appointment. Intravesical botulinum toxin injection was the second line treatment in ten patients. 94% of patients had an end fill pressure below 40 cm HO in their last IUD. 82% were socially continent (dry or occasional damp patches) with or without catheterisations at the age of 11.5 years. One patient in the cohort had bladder augmentation.

Conclusion: The optimal management of neuropathic bladder secondary to spina bifida remains controversial. Bladder and renal functional outcomes can be improved with close monitoring and less invasive management.

References
1.
Higuchi T, Granberg C, Fox J, Husmann D . Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010; 184(6):2492-6. DOI: 10.1016/j.juro.2010.08.038. View

2.
Naqvi S, Clothier J, Wright A, Garriboli M . Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A. J Urol. 2019; 203(2):413-419. DOI: 10.1097/JU.0000000000000540. View

3.
Malakounides G, Lee F, Murphy F, Boddy S . Single centre experience: long term outcomes in spina bifida patients. J Pediatr Urol. 2013; 9(5):585-9. DOI: 10.1016/j.jpurol.2013.02.015. View

4.
Tanaka S, Yerkes E, Routh J, Tu D, Austin J, Wiener J . Urodynamic characteristics of neurogenic bladder in newborns with myelomeningocele and refinement of the definition of bladder hostility: Findings from the UMPIRE multi-center study. J Pediatr Urol. 2021; 17(5):726-732. PMC: 11008495. DOI: 10.1016/j.jpurol.2021.04.019. View

5.
Austin P, Bauer S, Bower W, Chase J, Franco I, Hoebeke P . The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2015; 35(4):471-81. DOI: 10.1002/nau.22751. View